Results 1 to 10 of about 28,686 (70)

Targeting EpCAM expression via near-infrared fluorescent antibodies enables microscopic delineation of primary and recurrent HNSCC. [PDF]

BMC Cancer
Uhl B, Eggert D, Smiljanov B, von Thun Und Hohenstein K, Walz C, Kranz G, Schwenk-Zieger S, Haring F, Luft J, Song J, Holtmann V, Baumeister P, Reichel CA, Gires O, Canis M, Betz C.   +15 more
europepmc   +1 more source

Metabolic-immune crosstalk in head and neck squamous cell carcinoma: CD44 and APP identified as causal therapeutic targets via integrated lactylation-Mendelian randomization analysis. [PDF]

Front Immunol
Zhang X, Deng Q, Yang L, Yan M.
europepmc   +1 more source

From Berry to Bedside: Translational Potential of Berry-Derived Phytochemicals in HNSCC. [PDF]

Molecules
Nyati KK, Ramalingam R, Shrestha S, Jagadeesha S, Dasari S, Masood S, Yade M, Mehta PA, Kundety S, Oghumu S.   +9 more
europepmc   +1 more source

Flow-cytometric profiling of large extracellular vesicles as immunophenotypic biomarkers in head and neck squamous cell carcinoma. [PDF]

Cancer Immunol Immunother
Büntzel J, Maulhardt M, Angleitner AC, Schulz M, Köberle D, Naser S, Zwerenz C, Pagel CF, Hille A, Hund AC, Büntzel J.   +10 more
europepmc   +1 more source

Clinical and economic burden of recurrence among older patients with locoregionally advanced head and neck squamous cell carcinoma in the United States. [PDF]

J Manag Care Spec Pharm
Zheng D, Zhang S, Bidadi B, Lerman N, Song Y, Tang Y, Song R, Li J, Zhu A, Signorovitch J, Merchant S, Hanna GJ.   +11 more
europepmc   +1 more source

Basic and Clinical Evidence for Perioperative Immunotherapy in Resectable HNSCC. [PDF]

Cancers (Basel)
Sakaue S, Kono M, Kumai T, Inoue T, Ominato H, Takahara M.   +5 more
europepmc   +1 more source

ZBP1 Drives CD8+ T cell-mediated anti-tumor immunity in head and neck squamous cell carcinoma. [PDF]

PLoS Genet
Min Y, Song G, Yang L, He L, Xu S, Gao K, Liu Z, Peng X, Dai L.   +8 more
europepmc   +1 more source

The Silent Link: Exploring the Impact of Periodontal Diseases on Head and Neck Carcinogenesis. [PDF]

Clin Exp Dent Res
Afshar Y, Rezaei N.
europepmc   +1 more source

Antibody-drug conjugates in recurrent or metastatic HNSCC: relevant targets, clinical development, and future prospects. [PDF]

Front Immunol
Zhao H, Zhang S, Wang F, Yu P, Li J, Jia L, He P, Liu R, Zhang J, Wang K, Han R, Huangfu H.   +11 more
europepmc   +1 more source

SFXN3 Serves as a Predictive Biomarker for Cisplatin Response and Survival in Head and Neck Squamous Cell Carcinoma. [PDF]

Oncol Res
Jeong EJ, Kim YS, Lee Y, Ryu JS, Choi YH, Kim E.   +5 more
europepmc   +1 more source